Collegium Pharmaceutical (COLL) Finished Goods (2016 - 2025)

Collegium Pharmaceutical has reported Finished Goods for 10 years, with the latest figure at $20.2 million in Q3 2025.

• On a quarterly basis, Finished Goods rose 23.13% year-over-year to $20.2 million in Q3 2025; TTM through Sep 2025 was $20.2 million, a 23.13% increase from a year earlier, with the FY2024 full-year figure at $17.8 million, up 17.12% from the prior year.
• Finished Goods was $20.2 million for Q3 2025 at Collegium Pharmaceutical, roughly flat from $20.2 million in the prior quarter.
• The five-year high for Finished Goods was $36.9 million in Q1 2022, with the low at $9.5 million in Q2 2021.
• Average Finished Goods over 5 years is $16.5 million, with a median of $15.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Finished Goods jumped 280.78% in 2022, then plunged 62.81% in 2023.
• Over 5 years, Finished Goods stood at $12.7 million in 2021, then gained by 27.77% to $16.2 million in 2022, then slipped by 6.29% to $15.2 million in 2023, then increased by 17.12% to $17.8 million in 2024, then rose by 13.64% to $20.2 million in 2025.
• The last three Finished Goods figures came in at $20.2 million (Q3 2025), $20.2 million (Q2 2025), and $18.5 million (Q1 2025), per Business Quant data.